JB Chemicals & Pharmaceuticals Ltd.

NSE: JBCHEPHARM  SECTOR: Pharmaceuticals & Drugs

956.4
+36.6 (3.98%)

Price Summary

Today's High

₹ 966.6

Today's Low

₹ 934.55

52 Week High

₹ 1150

52 Week Low

₹ 321.7

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.

Company Essentials

Market Cap

7391.25975708 Cr.

Enterprise Value

7411.73295708 Cr.

No. of Shares

7.7282097 Cr.

P/E

22.34

P/B

4.72

Face Value

₹ 2

Div. Yield

1.15%

Book Value (TTM)

₹  202.7916

CASH

11.5629 Cr.

DEBT

32.0361 Cr.

Promoter Holding

55.91%

EPS (TTM)

₹  42.8197

Sales Growth

9.29647006002581%

ROE

18.3042624218941 %

ROCE

22.9425044505166 %

Profit Growth

16.3428258539234 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1w1m3m6m1Yr3Yr5Yr

* Prices are based on daily market changes.

Valuation Chart 1w1m3m6m1Yr3Yr5Yr

* The chart is based on the standalone earnings of the company.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

Sales Growth (in Cr.)

1 Year9.3%
3 Year11.03%
5 Year9.1%

Profit Growth (in Cr.)

1 Year47.28%
3 Year15.74%
5 Year18.74%

ROE%

1 Year18.3%
3 Year13.24%
5 Year13.79%

ROCE %

1 Year22.94%
3 Year17.92%
5 Year17.71%

Debt/Equity

0.0221658506371175

Price to Cash Flow

27.22

Interest Cover Ratio

108.3407409749

CFO/PAT (5 Yr. Avg.)

0.991259891480637

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2020 55.91 0
Dec 2019 55.68 0
Sep 2019 56.02 0
Jun 2019 56.02 0
Mar 2019 56.02 0
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 15.7364842536698% for the Past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 108.3407409749.
  • Company’s PEG ratio is 0.422104284043959.
  • The company has an efficient Cash Conversion Cycle of 87.3989660432595 days.
  • Company has a healthy liquidity position with current ratio of 2.44556068317866.
  • The company has a good cash flow management; CFO/PAT stands at 0.991259891480637.
  • The company has a high promoter holding of 55.91%.

 Limitations

  • The company has shown a poor revenue growth of 11.0309806366217% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2019 Sep 2019 Dec 2019 Mar 2020 Jun 2020
Net Sales 410.8 428.12 384.96 416.87 489.62
Total Expenditure 318.55 327.36 300.87 325.73 331.47
Operating Profit 92.25 100.76 84.08 91.14 158.15
Other Income 12.34 18.11 16.02 2.88 22.54
Interest 0.8 0.87 0.85 0.4 3.73
Depreciation 15.63 16.22 16.55 16.69 16.97
Exceptional Items 0 0 0 -10 0
Profit Before Tax 88.16 101.77 82.71 66.92 159.99
Tax 29.01 5.82 20.53 16.06 38.07
Profit After Tax 59.15 95.96 62.17 50.87 121.93
Adjusted EPS (Rs) 0.74 1.2 0.77 0.66 1.58

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Net Sales 1164.94 1198.69 1254.99 1501.19 1640.74
Total Expenditure 939.21 980.15 1072.79 1212.75 1272.5
Operating Profit 225.72 218.54 182.2 288.44 368.24
Other Income 55.68 49.51 56.21 40.23 49.57
Interest 10.29 5 3.41 4.57 3.16
Depreciation 40.41 46.26 55.95 54.82 65.09
Exceptional Items 0 0 0 0 -10
Profit Before Tax 230.69 216.78 179.04 269.28 339.56
Tax 51.49 43.82 51.04 87.22 71.42
Net Profit 179.2 172.96 128 182.06 268.14
Adjusted EPS (Rs.) 21.13 20.39 15.32 22.69 34.7

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Equity and Liabilities
Share Capital 16.96 16.96 16.71 16.05 15.46
Total Reserves 1205.74 1370.9 1436.67 1468.52 1429.83
Borrowings 0 0 0 0 0
Other N/C liabilities 46.07 41.79 62.98 79.08 73.29
Current liabilities 735.89 666.97 711.89 763.27 493.12
Total Liabilities 2004.67 2096.62 2228.25 2326.91 2011.71
Assets
Net Block 369.35 608.69 569.91 552.11 583.21
Capital WIP 134.19 3.76 17.4 15.09 16.17
Investments 364.38 318.81 182.92 228.84 202.42
Loans & Advances 22.63 9.22 10 8.31 3.59
Other N/C Assets 1.04 0.88 1.03 0.59 0.36
Current Assets 1113.08 1155.26 1446.99 1521.97 1205.97
Total Assets 2004.67 2096.62 2228.25 2326.91 2011.71
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Profit Before Tax 230.69 216.78 179.04 269.28 339.56
Adjustment -9.63 10.01 14.73 26.87 15.19
Working Capital Changes 1.15 -0.3 -39.95 -42.44 3.97
Tax Paid -51.34 -48.92 -37.95 -61.08 -87.15
Operating Cash Flow 170.87 177.58 115.87 192.63 271.57
Investing Cash Flow -51.69 -42.45 -23.97 -27.93 24.18
Financing Cash Flow -97.46 -164.84 -59.44 -155.66 -305.48
Net Cash Flow 21.72 -29.71 32.45 9.05 -9.73

Corporate Actions

Ratings & Research Reports

Company Presentations

Company News

JB Chem & Pharma Stock Price Analysis and Quick Research Report. Is JB Chem & Pharma an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into JB Chem & Pharma and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 271.5717 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. JB Chem & Pharma has a Debt to Equity ratio of 0.0221658506371175 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In JB Chem & Pharma , the EPS growth was 52.9146816040335 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, JB Chem & Pharma has OPM of 22.4437517507297 % which is a good sign for profitability.
     
  • ROE: JB Chem & Pharma have a average ROE of 18.3042624218941 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about JB Chem & Pharma

X